Akari Therapeutics, Plc (AKTX)
$0.5
-0.03 (-5.32%)
Rating:
Recommendation:
Buy
| Symbol | AKTX |
|---|---|
| Price | $0.5 |
| Beta | 1.436 |
| Volume Avg. | 0.08M |
| Market Cap | 37.225M |
| Shares () | - |
| 52 Week Range | 0.38-1.61 |
| 1y Target Est | - |
| DCF Unlevered | AKTX DCF -> | |
|---|---|---|
| DCF Levered | AKTX LDCF -> | |
| ROE | -184.77% | Strong Sell |
| ROA | -159.14% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 36.58% | Neutral |
| P/E | - | |
| P/B | 3.56 | Strong Buy |
Latest AKTX news
About
Download (Excel)Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.